Morningstar, Inc. - August 5, 2025
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum?
Plus: Has the ‘Buffett Premium’ Gone Away for Berkshire Stock?
 Morning DigestAugust 5, 2025 Gabe Alpert, Tom Lauricella Drug stocks take a hit in the latest headwind for the healthcare sector. 
ADVERTISEMENT  Editor's Picks  Shares of Berkshire have plunged more than 12% since May. Sarah Hansen  Plus, a huge fair value increase for one Mag 7 stock. David Sekera, Susan Dziubinski  Confused about which vehicles to fund first? We can help. Christine Benz Investing Insights American Electric and JM Smucker are among July’s high-yielding winners. Bella Albrecht Microsoft and Public Storage are among the stocks that fell into undervalued territory. Bella Albrecht AMD and Intuit are among the stocks rated as expensive. Bella Albrecht A well-diversified portfolio and low fee give this fund an edge. Brendan McCann A recent deferred interest payment has sent bond prices tumbling. Max Curtin And why there’s more to the story when it comes to non-US equities as a value play. Jess Bebel These seven undervalued utilities stocks look attractive today. Tori Brovet A key provision of the new award is that Musk must remain in a senior leadership position at Tesla. Seth Goldstein Recent Earnings New Stock Analyst Reports In the second quarter, Waters (WAT) generated 8% constant-currency sales growth, above management's prior outlook of 5%-7%, and adjusted EPS of $2.95, at the high end of guidance of $2.88-$2.98. Management raised its 2025 outlook slightly in response to this news. The firm is delivering more-normal results despite uncertainty in the US academic and government market, which is being more than offset by strength from its biopharmaceutical end market, decent industrial results, and rebounding trends in China. By product, we remain impressed by instrument sales, which grew 5% in the quarter. New Fund Analyst Reports Royce Small-Cap Total Return (RYTRX) has evolved but remains attractive. This old strategy has a fresh and promising management team. Lead manager Miles Lewis joined the firm and fund from American Century in May 2020 as forerunner Chuck Royce’s heir apparent. Since taking over in May 2021 he has built his own team, put his stamp on the process and portfolio, and delivered solid results. The squad consists of comanager Joe Hintz, whom Lewis recruited from American Century; assistant manager Jag Sriram, a well-regarded Royce analyst since 2020; and newer analyst Matt Fedorjaka. The Tools You Need to Invest Like an Analyst Stay connected:
|
